$SNSS Assuming event based payment from Day One Bio (DOT-1 / Canaan partners) is one thing. But the big picture here is that the probability of DAY101 into clinical has increased tremendously as they obtained Complete Response for two of eight patients in 10.5 weeks and also obtained FDA Breakthrough Therapy Designation (BTD) & Orphan status ๐Ÿ‘ .. This brought Sunesis closer (highest probability with less risk) to $57M pre-commercialization payments and royalties from sales
  • 10